Introducing New Proficiency Tests – An Overview of the Prototype Proficiency Tests

Company
Proficiency Test
Year
AstraZeneca
BRCA/HRR Prostate carcinoma (tissue)
2020
AstraZeneca
BRCA 1/2 (Phase II) ovarian carcinoma
2017
AstraZeneca
T790M (Phase I) NSCLC
2016
AstraZeneca
T790M (Phase II) NSCLC
2017
Bayer
NTRK Genetic fusion
2019
Blueprint Medicines
GIST (Adaptation proficiency test)
2020
Bristol-Myers Squibb
PD-L1 malignant melanoma
2016
Bristol-Myers Squibb/Merck Sharp & Dohme
PD-L1 NSCLC (Phase II)
2017
Janssen Cilag
FGFR3 Urothelial carcinoma
2020
Lilly
EGFR IHC sqNSCLC
2016
Lilly
RET-Genetic fusion (ISH and NGS)
2021
Lilly
RET-Mutations
2021
Merck Sharp & Dohme
PD-L1 NSCLC (Phase I)
2016
Merck Sharp & Dohme
PD-L1 HNSCC
2020
Merck Sharp & Dohme
PD-L1 Urothelial carcinoma (Phase II)
2020
Merck Sharp & Dohme/ Roche
PD-L1 Urothelial carcinoma (Phase I)
2019
Merck Sharp & Dohme/ Roche
PD-L1 TNBC
2019
Novartis
BRAF V600 NSCLC
2017
Novartis
PIK3CA mamma carcinoma
2020
Pierre Fabre
BRAF V600E Colon carcinoma
2020
Pfizer
ROS1 NSCLC
2019
Roche
ALK NSCLC
2019
Astellas
Claudin 18.2
2023
AstraZeneca
HER2low
2023
AstraZeneca
HRD Ovarial carcinoma
2022
Servier
IDH1 Cholangio carcinoma
2023
MERCK / Novartis
MET Exon 14 Skipping NSCLC Tissue
2022
MERCK / Novartis
MET Exon 14 Skipping NSCLC Liquid Biopsy
2022

 

Status 01/2023